- PureTech Health said affiliate company Karuna Pharmaceuticals had started a key study for a treatment for psychosis in schizophrenia.

The so-called Phase 2 study would test least product candidate KarXT, or Karuna-Xanomeline-Trospium.

In a previous study, the treatment successfully demonstrated tolerability at a dose level exceeding those shown to be efficacious in previous studies of xanomeline alone.

Top-line data results of this latest study were expected at the end of 2019.

'"We are pleased with the progress Karuna has made to advance KarXT into a Phase 2 study, bringing us one step closer to potentially delivering the first new mechanism in more than 60 years for the treatment of psychosis in schizophrenia,' chief of research and strategy Eric Elenko said.

At 8:20am: [LON:PRTC] PureTech Health Plc share price was 0p at 161p

Story provided by